SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare (IXHL) is experiencing a surge in momentum, largely driven by its imminent NASDAQ compliance and intense speculation surrounding potential positive End-of-Phase 2 results for its Fast Track-designated sleep apnea drug. The community is actively discussing the stock's severely undervalued market cap relative to its cash and pipeline, anticipating a significant re-rating and potential short squeeze from the newly tightened float.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending after reporting robust quarterly earnings, including beats on revenue and EPS, achieving full-year GAAP profitability, and announcing a significant new share buyback, which sparked a perplexing after-hours dip. The community is actively debating whether this decline is market manipulation or an exceptional buying opportunity, particularly given the company's strategic pivot into Agentic AI and discussions around potential government contracts.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending after achieving a successful and flawless launch of its Alpha rocket, a key event that has ignited widespread community excitement and renewed investor confidence. This successful mission, following prior delays, is driving discussions about the company's potential within the expanding space and defense sectors.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending on strong anticipation of a major hyperscaler tenant announcement for its expanding AI data center campus, amplified by recent strategic land acquisitions for significant power generation capacity. The community is buzzing about its potential in the critical energy-digital infrastructure sector, despite some impatience surrounding the timing of the official news.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating attacks disrupt shipping in the Strait of Hormuz, driving crude oil prices higher despite a historic 400 million barrel global reserve release, fueling a sharp debate among investors on whether prices will continue to surge or eventually crash.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron is actively discussed due to recent label expansions for its oncology drug Libtayo and promising gene therapy data for hearing loss, bolstering its diverse pipeline, even as persistent manufacturing issues delay a key Eylea HD pre-filled syringe and intensify market competition in ophthalmology.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending due to its upcoming Q4/FY2025 earnings report and highly anticipated Navenibart data from the ALPHA-SOLAR trial, building on the recent Astria Therapeutics acquisition and ORLADEYO's pediatric approval, with the community actively debating significant short interest and the drug's potential for best-in-class dosing.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

Investors are actively debating the high distribution yield of Icahn Enterprises and potential for a short squeeze, fueled by optimism surrounding its CVI Energy holdings benefiting from current energy market dynamics and its indirect exposure to a possible SpaceX IPO. This comes as the company continues strategic asset realignments and Carl Icahn makes new investments, keeping the community focused on dividend sustainability and future growth.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell is trending as geopolitical tensions in the Middle East elevate crude oil and natural gas prices, with the community noting significant LNG supply disruptions following force majeure declarations from Qatar and Shell. Investors are also discussing Shell's ongoing share buybacks and strategic asset realignments as contributing factors to its recent bullish momentum.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as analysts, including JPMorgan and Citigroup, raise price targets to $45 and $57 respectively, while investors eagerly anticipate upcoming data presentations at the ASH conference. The community is actively debating the company's significant undervaluation, strong commercial traction of its oncology drugs Revuforj and Niktimvo, and escalating buyout speculation, particularly with partner Incyte.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


3jun88net2

Jun88